248 related articles for article (PubMed ID: 38391958)
21. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
[TBL] [Abstract][Full Text] [Related]
22. The mutational profile of sporadic epithelial ovarian carcinoma.
Kalamanathan S; Bates V; Lord R; Green JA
Anticancer Res; 2011 Aug; 31(8):2661-8. PubMed ID: 21778320
[TBL] [Abstract][Full Text] [Related]
23. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
[TBL] [Abstract][Full Text] [Related]
24. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
25. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
[TBL] [Abstract][Full Text] [Related]
26. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
[TBL] [Abstract][Full Text] [Related]
27. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
[TBL] [Abstract][Full Text] [Related]
28. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
29. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Catasus L; Gallardo A; Cuatrecasas M; Prat J
Mod Pathol; 2009 Apr; 22(4):522-9. PubMed ID: 19234438
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
31. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
[TBL] [Abstract][Full Text] [Related]
32. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
[TBL] [Abstract][Full Text] [Related]
33. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
Bosse T; ter Haar NT; Seeber LM; v Diest PJ; Hes FJ; Vasen HF; Nout RA; Creutzberg CL; Morreau H; Smit VT
Mod Pathol; 2013 Nov; 26(11):1525-35. PubMed ID: 23702729
[TBL] [Abstract][Full Text] [Related]
34. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
Vang R; Shih IeM; Kurman RJ
Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
[TBL] [Abstract][Full Text] [Related]
35. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
[TBL] [Abstract][Full Text] [Related]
36. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
37. Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women.
Cho YH; Kim DY; Kim JH; Kim YM; Kim KR; Nam JH; Kim YT
Yonsei Med J; 2009 Apr; 50(2):266-72. PubMed ID: 19430562
[TBL] [Abstract][Full Text] [Related]
38. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
39. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis.
Mehra K; Mehrad M; Ning G; Drapkin R; McKeon FD; Xian W; Crum CP
Front Biosci (Elite Ed); 2011 Jan; 3(2):625-34. PubMed ID: 21196340
[TBL] [Abstract][Full Text] [Related]
40. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]